Clarity PharmaceuticalsASX:CU6 -11.03%39 Quick Ratio is 11.43 as of Dec. 2025, which is 9% below its 10-year median of 12.51. GuruFocus rates ASX:CU6 with a GF Score™ of 39/100. The stock has 2 warning signs investors should review. Among 1,413 Biotechnology companies, Clarity Pharmaceuticals ranks better than 81.53% on this metric.
Clarity Pharmaceuticals has a quick ratio of 11.43. It generally indicates good short-term financial strength.
The historical rank and industry rank for Clarity Pharmaceuticals's Quick Ratio or its related term are showing as below:
ASX:CU6'
s Quick Ratio Range Over the Past 10 Years
Min: 9.69 Med: 12.51 Max: 58.83
Current: 11.43
During the past 4 years, Clarity Pharmaceuticals's highest Quick Ratio was 58.83. The lowest was 9.69. And the median was 12.51.
ASX:CU6's Quick Ratio is ranked better than 81.53% of 1413
companies
in the Biotechnology industry
Industry Median: 3.6
vs ASX:CU6: 11.43
Clarity Pharmaceuticals (ASX:CU6) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Clarity Pharmaceuticals Quick Ratio Related Terms
Clarity Pharmaceuticals Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CU6 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Clarity Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clarity Pharmaceuticals Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clarity Pharmaceuticals's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Clarity Pharmaceuticals's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Clarity Pharmaceuticals's Quick Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clarity Pharmaceuticals (ASX:CU6) has a Quick Ratio of 11.43 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Clarity Pharmaceuticals and its competitors. This is near median its historical median of 12.51. Over the past decade, Clarity Pharmaceuticals' Quick Ratio has ranged from 9.69 to 58.83. According to the industry distribution chart, Clarity Pharmaceuticals ranks #261 out of 1413 companies in the Biotechnology industry, placing it in the top 18.5%.
Is Clarity Pharmaceuticals' Quick Ratio too high?
Clarity Pharmaceuticals' current Quick Ratio of 11.43 is near median its 10-year median of 12.51. Over the past 10 years, this metric has ranged from a low of 9.69 to a high of 58.83. The Biotechnology industry median Quick Ratio is 3.60. Clarity Pharmaceuticals' value of 11.43 is 217.5% above this industry median. Based on the distribution chart, Clarity Pharmaceuticals ranks #261 out of 1413 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Clarity Pharmaceuticals has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Clarity Pharmaceuticals' Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clarity Pharmaceuticals ranks #261 out of 1413 companies for Quick Ratio. This places Clarity Pharmaceuticals in the top 19% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Clarity Pharmaceuticals' value of 11.43 is 217.5% above this benchmark. Historically, Clarity Pharmaceuticals' own Quick Ratio has ranged from 9.69 to 58.83 over the past decade. While the company's 10-year median is 12.51 vs. the industry median of 3.60, Clarity Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clarity Pharmaceuticals's current Quick Ratio of 11.43 is 217.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Clarity Pharmaceuticals and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clarity Pharmaceuticals's current Quick Ratio is 11.43, which is near median its own 10-year median of 12.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clarity Pharmaceuticals stock overvalued right now?
Clarity Pharmaceuticals (ASX:CU6) has a current Quick Ratio of 11.43. The current Quick Ratio is 11.43, which is near median its 10-year median of 12.51 and 217.5% above the Biotechnology industry median of 3.60. Clarity Pharmaceuticals' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Clarity Pharmaceuticals (ASX:CU6), the current Quick Ratio is 11.43 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.
39GF Score
Get the complete analysis for ASX:CU6
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CU6 has been successfully added to your 
